[go: up one dir, main page]

MX2018015269A - Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos. - Google Patents

Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.

Info

Publication number
MX2018015269A
MX2018015269A MX2018015269A MX2018015269A MX2018015269A MX 2018015269 A MX2018015269 A MX 2018015269A MX 2018015269 A MX2018015269 A MX 2018015269A MX 2018015269 A MX2018015269 A MX 2018015269A MX 2018015269 A MX2018015269 A MX 2018015269A
Authority
MX
Mexico
Prior art keywords
methods
thailanstatin
synthesis
derivatives
treatment
Prior art date
Application number
MX2018015269A
Other languages
English (en)
Inventor
C Nicolaou Kyriacos
Rhoades Derek
M Kumar Soundarapandian
R Pattanayak Manas
LAMANI Manjunath
Original Assignee
Univ Rice William M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rice William M filed Critical Univ Rice William M
Publication of MX2018015269A publication Critical patent/MX2018015269A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En un aspecto. la presente divulgación provee análogos de tailanstatina de la fórmula: R4 R6 X1 y0 R O Y1 O Rs N Ra 7 R8 Ril (1) en donde las variables son como se define en la presente. En otro aspecto, la presente divulgación también provee métodos de preparación de los compuestos divulgados en la presente. En otro aspecto, la presente divulgación también provee composiciones farmacéuticas y métodos de uso de los compuestos divulgados en la presente.
MX2018015269A 2016-06-08 2017-06-08 Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos. MX2018015269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347448P 2016-06-08 2016-06-08
PCT/US2017/036589 WO2017214423A2 (en) 2016-06-08 2017-06-08 Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof

Publications (1)

Publication Number Publication Date
MX2018015269A true MX2018015269A (es) 2019-09-18

Family

ID=60578962

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015269A MX2018015269A (es) 2016-06-08 2017-06-08 Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.

Country Status (8)

Country Link
US (1) US11584754B2 (es)
EP (1) EP3468976A4 (es)
JP (1) JP2019524650A (es)
AU (1) AU2017277786A1 (es)
CA (1) CA3027029A1 (es)
MA (1) MA45258A (es)
MX (1) MX2018015269A (es)
WO (1) WO2017214423A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3037883A1 (en) * 2016-09-23 2018-03-29 Purdue Research Foundation Anti-cancer agents and preparation thereof
CN111788208B (zh) 2017-09-20 2023-11-24 Ph制药有限公司 泰兰他汀类似物
JP2023521135A (ja) * 2020-04-09 2023-05-23 ブリストル－マイヤーズ スクイブ カンパニー メアヤマイシン類似体および使用方法
AU2024257248A1 (en) * 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825267B2 (en) 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
WO2009031999A1 (en) * 2007-09-07 2009-03-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fr901464 and analogs with antitumor activity and method for their preparation
IN2014MN00242A (es) * 2011-08-27 2015-09-25 Marrone Bio Innovations Inc
RU2618523C2 (ru) 2012-11-05 2017-05-04 Пфайзер Инк. Аналоги сплицеостатина
EA035262B1 (ru) * 2013-11-19 2020-05-21 Пюрдью Рисёрч Фаундейшн Противораковые агенты и их получение

Also Published As

Publication number Publication date
WO2017214423A2 (en) 2017-12-14
EP3468976A4 (en) 2019-11-27
CA3027029A1 (en) 2017-12-14
AU2017277786A1 (en) 2019-01-03
JP2019524650A (ja) 2019-09-05
US20200024283A1 (en) 2020-01-23
WO2017214423A8 (en) 2018-04-05
MA45258A (fr) 2019-04-17
US11584754B2 (en) 2023-02-21
EP3468976A2 (en) 2019-04-17
WO2017214423A3 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
DOP2017000304A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2018000270A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO2018012171A2 (es) Piridinas sustituidas con heteroarilo y métodos de uso
SV2017005589A (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen
NI201800076A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20170590A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO2018013141A2 (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen
GT201700190A (es) Desacetoxitubulisina h y análogos de esta
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
UY38423A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
PE20180658A1 (es) Sintesis total de shishijimicina a y sus analogos
ECSP17046657A (es) Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina